

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:

Shi et al.

Docket No.: PF398D1

Application No.: Not Yet Assigned

Confirmation No.:

Filed: Concurrently Herewith

Art Unit: N/A

For: POLYNUCLEOTIDES ENCODING A  
NOVEL INTERLEUKIN RECEPTOR  
TERMED INTERLEUKIN-17 RECEPTOR-  
LIKE PROTEIN

---

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references A-BD listed on the attached Form PTO/SB/08A.

Copies of references A-BD were submitted by Applicants or cited by the Examiner in connection with the parent U. S. Patent Application Serial No. 09/154,219, filed September 16, 1998; to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of references A-BD. Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NO:229467 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached revised form PTO/SB/08 was submitted as reference BP, on August 6, 2002, in parent application Serial No. 09/145,219.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.


Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Dated: October 17, 2003

Respectfully submitted,

By   
Janet M. Martineau

Registration No.: 46,903  
HUMAN GENOME SCIENCES, INC.  
9410 Key West Avenue  
Rockville, Maryland 20850  
(301) 315-2723

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Yanggu Shi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PF398D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	5,194,596	03-16-1993	California Biotechnology Inc.	
	B	5,350,836	09-27-1994	Ohio University	
	C	09/912,293		Rosen et al.	Pages 1-75 (pages 1 and 2 partially redacted); portion of Table 2; SEQ ID NO:229467
	D	US-5,869,286	02-09-1999	YAO et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	E	WO00/15759	03-23-2000	HUMAN GENOME SCIENCES, INC.		
	F	WO00/55204	09-21-2000	HUMAN GENOME SCIENCES, INC.		
	G	WO99/14240	03-25-1999	HUMAN GENOME SCIENCES, INC.		
	H	WO95/14772	06-01-1995	MATSUBARA, KENICHI		
	I	WO98/20165-A1	05-14-1998	Whitehead Institute for Biomedical Research		
	J	WO98/58529-A1	12-30-1998	Affymetrix, Inc.		
	K	WO99/35263-A1	07-01-1999	Immunex Corporation		
	L	WO96/29408	09-26-1996	Immunex Corporation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	M	YAO et al., "Immunity," 3:811-821 (1995).	
	N	DOERKS et al., Trends in Genetics 14:248-250, (1998).	
	O	SMITH et al., Nature Biotechnology 15:1222-1223, (1997).	
	P	BRENNER, Trends in Genetics 15:132-133, (1999).	
	Q	BORK, Trends in Genetics 12:425-427, (1998).	
	R	MASSAGUE, Cell 49:437-438, (1987).	
	S	PILBEAM et al., Bone 14:717-720, (1993).	
	T	SKOLNICK et al., Trends in Biotech 18:34-39, (2000).	
	U	BORK, Genome Research 10:398-400, (2000).	
	V	MURDOCH et al., Blood 95:3032-3043, (2000).	
	W	JI et al., J. Biol. Chem. 273:17299-17302, (1998).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Yanggu Shi
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	PF398D1

	X	BENJAMIN et al., Development 125:1591-1598, (1998).	
	Y	VUKICEVIC et al., PNAS USA 93:9021-9026, (1996).	
	Z	HILLIER et al., GenBank Accession Number AA677205, (Dec. 19, 1997).	
	AA	NCI-CGAP, GenBank Accession Number AI032064, (Aug. 28, 1998).	
	AB	NCI-CGAP, GenBank Accession Number AA847767, (Mar. 31, 1998).	
	AC	NCI-CGAP, GenBank Accession Number AA732635, (Jan. 23, 1998).	
	AD	NCI-CGAP, GenBank Accession Number AA832389, (Mar. 18, 1998).	
	AE	NCI CGAP, GenBank Accession Number AA836217, (Mar. 25, 1998).	
	AF	NCI-CGAP, GenBank Accession Number AI033911, (Aug. 28, 1998).	
	AG	NCI-CGAP, GenBank Accession Number AI034244, (Aug. 28, 1998).	
	AH	SHI Y. et al., "A Novel Cytokine Receptor-Ligand Pair", Journal of Biological Chemistry, 275:25, 19167-19176 (2000)	
	AI	ADAMS et al., GenBank Accession Number AQ309936, (Dec. 21, 1998).	
	AJ	ADAMS et al., GenBank Accession Number AQ240146, ((Sep. 28, 1998).	
	AK	ADAMS et al., GenBank Accession Number AQ113232, (Aug. 28, 1998).	
	AL	NCI-CGAP, GenBank Accession Number AA514396, (Aug. 18, 1997).	
	AM	NCI-CGAP, GenBank Accession Number AA287951, (Aug. 14, 1997).	
	AN	HILLIER et al., GenBank Accession Number W61239, (Oct. 15, 1996).	
	AO	HILLIER et al., GenBank Accession Number R74129, (Jun. 5, 1995).	
	AP	HILLIER et al., GenBank Accession Number H25941, (Jul. 10, 1995).	
	AQ	HILLIER et al., Gen Bank Accession Number T96740, (Mar. 27, 1995).	
	AR	HILLIER et al., GenBank Accession Number H25975, (Jul. 10, 1995).	
	AS	HILLIER et al., GenBank Accession Number T96629, (Mar. 27, 1995).	
	AT	LIEW, GenBank Accession Number N56060, (Feb. 20, 1996).	
	AU	HILLIER et al., GenBank Accession Number AA007528, (May 9, 1997).	
	AV	HILLIER et al., GenBank Accession Number AA007529, (May 9, 1997).	
	AW	HILLIER et al., GenBank Accession Number T97745, (Mar. 29, 1995).	
	AX	HILLIER et al., GenBank Accession Number R74038, (Jun. 5, 1995).	
	AY	HILLIER et al., GenBank Accession Number T98361, (Mar. 31, 1995).	
	AZ	OKUBO et al., GenBank Accession Number D25960, (Nov. 30, 1995).	
	BA	HILLIER et al., GenBank Accession Number T97852, (Mar. 29, 1995).	
	BB	HILLIER et al., GenBank Accession Number T98360, (Mar. 31, 1995).	
	BC	HILLIER et al., GenBank Accession Number W61238, (Oct. 15, 1996).	
	BD	Parnet, P. et al., "IL-1Rrp Is a Novel Receptor-like Molecule Similar to the Type I Interleukin-1 Receptor and Its Homologues T1/ST2 and IL-1R AcP," J. Biol. Chem. 271:3967-3970.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--